The small biotech company Graphite Bio said Thursday afternoon that it paused a study testing an experimental gene-editing therapy after the first treated patient suffered a serious side effect. The ...

Graphite Bio has agreed to merge into LENZ Therapeutics, creating a combined company focused on advancing LENZ’s lead pipeline candidates, designed to address presbyopia—nearly a year after Graphite ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to ...